Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond.

Chan JJ, Tan TJY, Dent RA.

Ther Adv Med Oncol. 2019 Oct 9;11:1758835919880429. doi: 10.1177/1758835919880429. eCollection 2019. Review.

2.

Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.

Yap YS, Leong MC, Chua YW, Loh KWJ, Lee GE, Lim EH, Dent R, Ng RCH, Lim JH, Singh G, Tan A, Guan G, Wu A, Lee YF, Bhagat AAS, Lim DW.

PLoS One. 2019 Sep 25;14(9):e0221305. doi: 10.1371/journal.pone.0221305. eCollection 2019.

3.

NICE guidance on dapagliflozin with insulin for type 1 diabetes.

Adler AI, Ting S, Dent R, Latimer N.

Lancet Diabetes Endocrinol. 2019 Oct;7(10):750-751. doi: 10.1016/S2213-8587(19)30265-7. Epub 2019 Sep 2. No abstract available.

4.

Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

Lai CPT, Yeong JPS, Tan AS, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH.

Breast Cancer Res Treat. 2019 Nov;178(2):295-305. doi: 10.1007/s10549-019-05396-5. Epub 2019 Aug 13.

PMID:
31410680
5.

The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.

Tan AS, Yeong JPS, Lai CPT, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH.

Virchows Arch. 2019 Aug 12. doi: 10.1007/s00428-019-02635-4. [Epub ahead of print]

PMID:
31407032
6.

Accurate GFR in obesity-protocol for a systematic review.

Sriperumbuduri S, Dent R, Malcolm J, Hiremath S, Klein R, White CA, Brown PA, Akbari A.

Syst Rev. 2019 Jun 22;8(1):147. doi: 10.1186/s13643-019-1052-2.

7.

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.

Gourley C, Balmaña J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E, Boulton SJ.

J Clin Oncol. 2019 Sep 1;37(25):2257-2269. doi: 10.1200/JCO.18.02050. Epub 2019 May 3.

PMID:
31050911
8.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.

PMID:
30977385
9.

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.

Yeong J, Lim JCT, Lee B, Li H, Ong CCH, Thike AA, Yeap WH, Yang Y, Lim AYH, Tay TKY, Liu J, Wong SC, Chen J, Lim EH, Iqbal J, Dent R, Newell EW, Tan PH.

J Immunother Cancer. 2019 Feb 6;7(1):34. doi: 10.1186/s40425-019-0499-y.

10.

Genome-wide identification of circulating-miRNA expression quantitative trait loci reveals the role of several miRNAs in the regulation of cardiometabolic phenotypes.

Nikpay M, Beehler K, Valsesia A, Hager J, Harper ME, Dent R, McPherson R.

Cardiovasc Res. 2019 Sep 1;115(11):1629-1645. doi: 10.1093/cvr/cvz030.

PMID:
30715214
11.

Genome-wide gene-based analyses of weight loss interventions identify a potential role for NKX6.3 in metabolism.

Valsesia A, Wang QP, Gheldof N, Carayol J, Ruffieux H, Clark T, Shenton V, Oyston LJ, Lefebvre G, Metairon S, Chabert C, Walter O, Mironova P, Lau P, Descombes P, Viguerie N, Langin D, Harper ME, Astrup A, Saris WH, Dent R, Neely GG, Hager J.

Nat Commun. 2019 Feb 1;10(1):540. doi: 10.1038/s41467-019-08492-8.

12.

Stabilization of oil-in-water emulsions with graphene oxide and cobalt oxide nanosheets and preparation of armored polymer particles.

Edgehouse K, Escamilla M, Wang L, Dent R, Pachuta K, Kendall L, Wei P, Sehirlioglu A, Pentzer E.

J Colloid Interface Sci. 2019 Apr 1;541:269-278. doi: 10.1016/j.jcis.2019.01.092. Epub 2019 Jan 23.

PMID:
30708243
13.

Obesity shows preserved plasma proteome in large independent clinical cohorts.

Cominetti O, Núñez Galindo A, Corthésy J, Valsesia A, Irincheeva I, Kussmann M, Saris WHM, Astrup A, McPherson R, Harper ME, Dent R, Hager J, Dayon L.

Sci Rep. 2018 Nov 19;8(1):16981. doi: 10.1038/s41598-018-35321-7.

14.

Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy.

Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A.

Mol Neurobiol. 2019 Jul;56(7):4741-4750. doi: 10.1007/s12035-018-1410-4. Epub 2018 Oct 31.

15.

ASCO Leadership Development Program: International Perspectives.

De Guzman R, Malik M, Lopes GL Jr, Dent RA, Dawood S.

J Glob Oncol. 2018 Sep;4:1-3. doi: 10.1200/JGO.18.00014. No abstract available.

16.

Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.

Laufs U, Dent R, Kostenuik PJ, Toth PP, Catapano AL, Chapman MJ.

Eur Heart J. 2019 Sep 1;40(33):2825-2830. doi: 10.1093/eurheartj/ehy479. No abstract available.

PMID:
30169643
17.

Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.

Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R, Rosenson RS.

Cardiovasc Drugs Ther. 2018 Aug;32(4):365-372. doi: 10.1007/s10557-018-6817-7.

PMID:
30073585
18.

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.

Yap YS, Singh AP, Lim JHC, Ahn JH, Jung KH, Kim J, Dent RA, Ng RCH, Kim SB, Chiang DY.

NPJ Breast Cancer. 2018 Jul 26;4:19. doi: 10.1038/s41523-018-0070-x. eCollection 2018.

19.

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

Mefford MT, Tajeu GS, Tanner RM, Colantonio LD, Monda KL, Dent R, Farkouh ME, Rosenson RS, Safford MM, Muntner P.

Am J Cardiol. 2018 Sep 1;122(5):768-774. doi: 10.1016/j.amjcard.2018.05.016. Epub 2018 Jun 2.

PMID:
30057227
20.

High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.

Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, Lye WK, Putti TC, Dent R, Lim E, Thike AA, Tan PH, Iqbal J.

Front Immunol. 2018 May 30;9:1209. doi: 10.3389/fimmu.2018.01209. eCollection 2018.

21.

What is the role of immunotherapy in breast cancer?

Tan TJ, Chan JJ, Kamis S, Dent RA.

Chin Clin Oncol. 2018 Apr;7(2):13. doi: 10.21037/cco.2018.04.01. Review.

22.

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Chan JJ, Tan TJY, Dent RA.

J Oncol Pract. 2018 May;14(5):281-289. doi: 10.1200/JOP.18.00034.

PMID:
29746805
23.

Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction.

Booth JN 3rd, Colantonio LD, Rosenson RS, Safford MM, Chen L, Kilgore ML, Brown TM, Taylor B, Dent R, Monda KL, Muntner P, Levitan EB.

J Am Heart Assoc. 2018 May 8;7(10). pii: e008462. doi: 10.1161/JAHA.117.008462.

24.

Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol.

Teo I, Singh R, Malhotra C, Ozdemir S, Dent RA, Kumarakulasinghe NB, Yeo WL, Cheung YB, Malhotra R, Kanesvaran R, Yee ACP, Chan N, Wu HY, Chin SM, Allyn HYM, Yang GM, Neo PSH, Nadkarni NV, Harding R, Finkelstein EA.

BMC Cancer. 2018 Apr 23;18(1):459. doi: 10.1186/s12885-018-4356-z.

25.
26.

ACSL5 genotype influence on fatty acid metabolism: a cellular, tissue, and whole-body study.

Rajkumar A, Liaghati A, Chan J, Lamothe G, Dent R, Doucet É, Rabasa-Lhoret R, Prud'homme D, Harper ME, Tesson F.

Metabolism. 2018 Jun;83:271-279. doi: 10.1016/j.metabol.2018.03.019. Epub 2018 Mar 29.

PMID:
29605434
27.

GreenCut protein CPLD49 of Chlamydomonas reinhardtii associates with thylakoid membranes and is required for cytochrome b6 f complex accumulation.

Wittkopp TM, Saroussi S, Yang W, Johnson X, Kim RG, Heinnickel ML, Russell JJ, Phuthong W, Dent RM, Broeckling CD, Peers G, Lohr M, Wollman FA, Niyogi KK, Grossman AR.

Plant J. 2018 Jun;94(6):1023-1037. doi: 10.1111/tpj.13915. Epub 2018 May 16. Erratum in: Plant J. 2019 Jun;98(5):953-954.

28.

Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.

Kramer B, Singh R, Wischusen J, Dent R, Rush A, Middlemiss S, Ching YW, Alexander IE, McCowage G.

Hum Gene Ther. 2018 Aug;29(8):874-885. doi: 10.1089/hum.2017.235. Epub 2018 Mar 23.

PMID:
29385852
29.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

30.

Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors.

Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A.

Psychooncology. 2018 Apr;27(4):1185-1192. doi: 10.1002/pon.4635. Epub 2018 Feb 1.

PMID:
29315963
31.

Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.

Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX, Dorajoo S, Foo KM, Loh KW, Koo SL, Chay WY, Tan TJY, Beh SY, Lim EH, Lee GE, Dent R, Yap YS, Ng R, Ho HK, Chan A.

Breast Cancer Res Treat. 2018 Apr;168(3):713-721. doi: 10.1007/s10549-017-4640-7. Epub 2018 Jan 8.

PMID:
29313215
32.

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.

Kim SB, Dent R, Wongchenko MJ, Singel SM, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Nov;18(11):e638. doi: 10.1016/S1470-2045(17)30785-4. Epub 2017 Oct 31. No abstract available. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667-e668.

PMID:
29208392
33.

Diet-resistant obesity is characterized by a distinct plasma proteomic signature and impaired muscle fiber metabolism.

Thrush AB, Antoun G, Nikpay M, Patten DA, DeVlugt C, Mauger JF, Beauchamp BL, Lau P, Reshke R, Doucet É, Imbeault P, Boushel R, Gibbings D, Hager J, Valsesia A, Slack RS, Al-Dirbashi OY, Dent R, McPherson R, Harper ME.

Int J Obes (Lond). 2018 Mar;42(3):353-362. doi: 10.1038/ijo.2017.286. Epub 2017 Nov 20.

34.

The role of feature-based discrimination in driving health disparities among Black Americans.

Dent RB, Hagiwara N, Stepanova EV, Green TL.

Ethn Health. 2017 Nov 6:1-16. doi: 10.1080/13557858.2017.1398314. [Epub ahead of print]

PMID:
29105509
35.

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.

Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D.

J Clin Lipidol. 2017 Nov - Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22.

PMID:
29066265
36.

Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study.

Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, Kilgore ML, Brown TM, Taylor B, Dent R, Muntner P, Levitan EB.

Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10). pii: e003626. doi: 10.1161/CIRCOUTCOMES.117.003626.

PMID:
29021332
37.

Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.

Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.

J Am Heart Assoc. 2017 Oct 2;6(10). pii: e005367. doi: 10.1161/JAHA.116.005367. Review.

38.

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F.

Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.

PMID:
28822332
39.

Is Type 2 Diabetes in Adults Associated With Impaired Capacity for Weight Loss?

Antoun G, Nikpay M, McPherson R, Harper ME, Dent R.

Can J Diabetes. 2018 Jun;42(3):313-316.e1. doi: 10.1016/j.jcjd.2017.06.010. Epub 2017 Aug 8. No abstract available.

PMID:
28800932
40.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.

41.

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

Descamps OS, Fraass U, Dent R, März W, Gouni-Berthold I.

Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12979. Epub 2017 Jul 27. Review.

42.

A prospective study of docetaxel-associated pain syndrome.

Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, Chiu L, Chow R, Wan BA, Pasetka M, Stinson J, Stacey E, Verma S, Lam H, Chow E, DeAngelis C.

Support Care Cancer. 2018 Jan;26(1):203-211. doi: 10.1007/s00520-017-3836-z. Epub 2017 Jul 22.

PMID:
28733699
43.

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

Boccara F, Dent R, Ruilope L, Valensi P.

Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. Review.

44.

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT.

JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.

45.

Primary Care Physician Perspectives on Barriers to Statin Treatment.

Tanner RM, Safford MM, Monda KL, Taylor B, O'Beirne R, Morris M, Colantonio LD, Dent R, Muntner P, Rosenson RS.

Cardiovasc Drugs Ther. 2017 Jun;31(3):303-309. doi: 10.1007/s10557-017-6738-x.

PMID:
28710589
46.

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Pećin I, Hartgers ML, Hovingh GK, Dent R, Reiner Ž.

Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23. Review.

48.

Novel Targeted Agents and Immunotherapy in Breast Cancer.

Mayer IA, Dent R, Tan T, Savas P, Loi S.

Am Soc Clin Oncol Educ Book. 2017;37:65-75. doi: 10.14694/EDBK_175631.

PMID:
28561712
49.

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.

Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES.

Cardiovasc Drugs Ther. 2017 Apr;31(2):187-195. doi: 10.1007/s10557-017-6727-0.

50.

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.

Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS.

J Am Coll Cardiol. 2017 Mar 21;69(11):1386-1395. doi: 10.1016/j.jacc.2016.12.036.

Supplemental Content

Support Center